About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 72207 record(s)
Req # A-2024-000179
Adverse Drug Reaction (ADR). Report number: E2B_06642692.Organization: Health Canada
August 2024
Req # A-2024-000185
Adverse Drug Reactions (ADRs). Report numbers: 001054745, 001076705.Organization: Health Canada
August 2024
Req # A-2024-000226
Adverse Drug Reactions (ADRs). Report numbers: 001081973, 001084219.Organization: Health Canada
August 2024
Req # A-2024-000227
Adverse Drug Reaction (ADR) for FAMCICLOVIR. Report number: E2B_07048452. ADR for ASAPHEN. Report number: 1077952. ADR for STOOL SOFTENER. Report number: E2B_07041973. ADR for RIVAROXABAN. Report number: 1077634.Organization: Health Canada
August 2024
Req # A-2024-000230
Adverse Drug Reactions (ADRs) for Dexilant. Report numbers: E2B_07047378, 001083404, 001083459, 001084337. ADRs for Ondansetron. Report numbers: E2B_07036937, E2B_07038477, E2B_07018563, E2B_07016780, 001083684.Organization: Health Canada
August 2024
Req # A-2024-000233
Adverse Drug Reactions (ADRs) for MEZAVANT. Report numbers: E2B_07024875, E2B_07024287, 001082743, E2B_07030498. ADRs for Mesalazine. Report numbers: E2B_07024290, E2B_07044749, E2B_07005577, E2B_07034218, E2B_07019303.Organization: Health Canada
August 2024
Req # A-2024-000234
Adverse Drug Reactions (ADRs) for VYVANSE. Report numbers: 001078818, 001084076, E2B_06993638. ADRs for C1 Esterase Inhibitor (Human). Report numbers: E2B_07053195, E2B_07025538, E2B_07017197. ADRs for GAMMAGARD LIQUID. Report numbers: 001080211,…Organization: Health Canada
August 2024
Req # A-2024-000242
Adverse Drug Reactions (ADRs). Report numbers: 001080559, 001078726, 001083827, 001080806, E2B_07049389, E2B_07047263, 001083763, 001077257, 001078054, E2B_07047631.Organization: Health Canada
August 2024
Req # A-2024-000250
Adverse Drug Reactions (ADRs). Report numbers: E2B_06980230, E2B_04724876, E2B_07005158, 001074116, 001079471, 001077365, 001083606.Organization: Health Canada
August 2024
Req # A-2024-000274
Adverse Drug Reactions (ADRs). Report numbers: E2B_07039945, E2B_07040159, E2B_07040430, E2B_07041494, E2B_07041838.Organization: Health Canada
August 2024